Stock GLAXO GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.

Equities

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
2,129 INR +3.05% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited +13.76% +12.14%
Apr. 25 GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology RE
Mar. 22 GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 220,202 210,953 244,012 281,714 224,319 361,301 - -
Enterprise Value (EV) 1 207,591 200,080 232,521 256,351 207,663 361,301 361,301 361,301
P/E ratio 49.4 x 226 x 68.1 x 16.6 x 36.7 x 53.1 x 47.1 x 41.7 x
Yield 1.54% 1.61% 2.08% 1.8% 2.42% 1.42% 1.48% 1.6%
Capitalization / Revenue 7.04 x 6.54 x 7.63 x 8.59 x 6.9 x 10.7 x 9.9 x 9.04 x
EV / Revenue 7.04 x 6.54 x 7.63 x 8.59 x 6.9 x 10.7 x 9.9 x 9.04 x
EV / EBITDA 36.7 x 32.1 x 35.1 x 34.1 x 27.9 x 41.7 x 36.9 x 32.6 x
EV / FCF 204 x 63 x 45.7 x 36.3 x 51 x 44 x 51.5 x 41.4 x
FCF Yield 0.49% 1.59% 2.19% 2.75% 1.96% 2.27% 1.94% 2.41%
Price to Book 10.3 x 11.6 x 16.3 x 10.6 x 12.9 x 19.8 x 18.3 x 16.3 x
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 - -
Reference price 2 1,300 1,245 1,440 1,663 1,324 2,133 2,133 2,133
Announcement Date 5/20/19 5/18/20 5/18/21 5/16/22 5/17/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 31,281 32,244 31,989 32,780 32,517 33,648 36,493 39,953
EBITDA 1 6,008 6,572 6,953 8,273 8,043 8,671 9,804 11,089
EBIT 1 5,522 5,746 6,160 7,592 7,385 8,450 9,571 10,911
Operating Margin 17.65% 17.82% 19.26% 23.16% 22.71% 25.11% 26.23% 27.31%
Earnings before Tax (EBT) 1 6,827 3,058 5,505 7,790 8,364 9,325 10,390 11,703
Net income 1 4,454 932 3,582 16,947 6,107 6,063 7,678 8,656
Net margin 14.24% 2.89% 11.2% 51.7% 18.78% 18.02% 21.04% 21.67%
EPS 2 26.29 5.500 21.14 100.0 36.05 40.20 45.30 51.10
Free Cash Flow 1 1,081 3,346 5,337 7,761 4,402 8,213 7,018 8,725
FCF margin 3.46% 10.38% 16.68% 23.68% 13.54% 24.41% 19.23% 21.84%
FCF Conversion (EBITDA) 17.99% 50.91% 76.75% 93.81% 54.73% 94.72% 71.58% 78.68%
FCF Conversion (Net income) 24.27% 359.01% 149.02% 45.8% 72.08% 135.46% 91.4% 100.79%
Dividend per Share 2 20.00 20.00 30.00 30.00 32.00 30.30 31.53 34.20
Announcement Date 5/20/19 5/18/20 5/18/21 5/16/22 5/17/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 8,572 8,138 7,900 10,099 8,159 8,096 7,451 9,169 8,023 7,874 7,617 9,129 8,555 8,396
EBITDA 1 2,055 1,709 1,517 2,765 1,978 1,752 1,489 2,569 2,287 1,697 1,439 2,351 2,354 2,098
EBIT 1 1,878 1,530 1,340 2,589 1,799 1,599 1,331 2,406 2,123 1,526 1,275 2,339 2,049 1,898
Operating Margin 21.91% 18.81% 16.96% 25.64% 22.05% 19.75% 17.86% 26.24% 26.46% 19.37% 16.74% 25.62% 23.95% 22.61%
Earnings before Tax (EBT) 1 2,114 630.1 1,649 2,735 1,718 2,078 1,600 2,622 2,242 1,900 1,810 2,701 2,327 2,168
Net income 1 1,565 143.3 1,211 2,042 1,504 12,190 1,193 1,934 1,646 1,334 1,322 1,998 1,294 1,610
Net margin 18.26% 1.76% 15.33% 20.22% 18.43% 150.57% 16.01% 21.1% 20.51% 16.94% 17.36% 21.89% 15.13% 19.18%
EPS 9.240 0.8500 7.150 12.06 8.880 71.96 7.040 11.42 9.710 7.880 - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/5/21 5/18/21 7/26/21 10/29/21 2/7/22 5/16/22 7/25/22 11/11/22 2/7/23 5/17/23 7/26/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 12,611 10,873 11,491 25,363 16,656 - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,081 3,346 5,337 7,761 4,402 8,213 7,018 8,725
ROE (net income / shareholders' equity) 21.2% 22.8% 21.6% 81.8% 27.7% 37.7% 40.2% 40.9%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 126.0 107.0 88.50 157.0 103.0 108.0 116.0 131.0
Cash Flow per Share - - - - - - - -
Capex 1 2,913 1,559 442 346 440 741 555 520
Capex / Sales 9.31% 4.84% 1.38% 1.06% 1.35% 2.2% 1.52% 1.3%
Announcement Date 5/20/19 5/18/20 5/18/21 5/16/22 5/17/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GlaxoSmithKline Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2,133 INR
Average target price
2,141 INR
Spread / Average Target
+0.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GLAXO Stock
  4. GLAXO Stock
  5. Financials GlaxoSmithKline Pharmaceuticals Limited